TransEnterix ALL IN ON ALF-X

Introduction to ALF-X Robotic Surgery System

At TransEnterix, we believe that advancements in robotic surgery must build on the success of laparoscopy and address the limitations of current robotic systems,…

Post A Reply

Report this entire thread

The reason we ask for your email address is to ensure the reporting feature is not abused. Once you report a thread a confirmation email will be sent to you requiring that you did in fact mean to do this action. This also gives us a way to get in touch with you privately to discuss your reasoning if we feel the thread has been reported without merit.

Your email address will never be used for any other reason and will never be sold to email marketers.

A reason is required.

I'm too lazy to check the outstanding shares of each company but .46 vs. .26 is darn close.

They're battling for tallest of the midgets.

post

Transenterix is becoming Titan real fast.

I'm too lazy to check the outstanding shares of each company but .46 vs. .26 is darn close.

post

They've barely generated revenue in Europe with Senhance. Does Pope actually believe they are going to have much more success in the states?

My best guess is they end up trying to work a deal with a teaching institution and basically give it away. Pope will try to bill the sale as an early success but I believe they're going to have an extremely hard time moving Senhance. Intuitive is king and they do not have the infrastructure to support a customer like Intuitive does.

SurgiBot is the only thing that can keep the company alive which is why you are seeing more loans. The loans are more for SurgiBot than they are Senhance. Similar to Titan's SPORT, Titan has diluted the company so much just trying to get the product to market. Expect similar challenges for TransEnterix.

Transenterix is becoming Titan real fast.

post

They've barely generated revenue in Europe with Senhance. Does Pope actually believe they are going to have much more success in the states?

My best guess is they end up trying to work a deal with a teaching institution and basically give it away. Pope will try to bill the sale as an early success but I believe they're going to have an extremely hard time moving Senhance. Intuitive is king and they do not have the infrastructure to support a customer like Intuitive does.

SurgiBot is the only thing that can keep the company alive which is why you are seeing more loans. The loans are more for SurgiBot than they are Senhance. Similar to Titan's SPORT, Titan has diluted the company so much just trying to get the product to market. Expect similar challenges for TransEnterix.

post

The Senhance System is a multi-port robotic surgery system which allows multiple robotic arms to control instruments and a camera vision system laparoscope. The system features advanced technology to enable surgeons with haptic feedback and the ability to move the laparoscopic camera via eye movement. The system replicates laparoscopic motion that is familiar to experienced surgeons, and integrates 3DHD vision technology. The Senhance System also offers responsible economics to hospitals by offering robotic technology with reusable instruments.

In April 2017, the Company submitted a 510(k) application to the Food and Drug Administration, or FDA, for the Senhance System.

http://ir.transenterix.com/secfiling.cfm?filingID=...


post

TRXC won't see $1 again until SurgiBot gets approved.

post

The same can be said for almost any other surgical procedure the robot is used for but marketing and technology always win out. If you are a surgeon, the train has already left the station and you should probably get on it.

Stock is going sub $1 by the end of the week.

post

Sorry, but there is no situation where you need a gigantic robot to fix the hernia.

The same can be said for almost any other surgical procedure the robot is used for but marketing and technology always win out. If you are a surgeon, the train has already left the station and you should probably get on it.

post

Hernia is the fastest growing robotic surgery market.

Sorry, but there is no situation where you need a gigantic robot to fix the hernia.

post

This news shouldn't be a surprise. Hernia is a enormous market. However, TransEnterix needs to figure out why Senhance isn't selling overseas. The U.S market is likely to be just as interested as the boys across the pond. Paul and his CEO need to come to the realization that their company is going to be burning cash until SurgiBot hits the market. That is the only product that matters to their business. Everything else is just a fluffer until it happens.

Hernia is the fastest growing robotic surgery market.

post

All in -

This news shouldn't be a surprise. Hernia is a enormous market. However, TransEnterix needs to figure out why Senhance isn't selling overseas. The U.S market is likely to be just as interested as the boys across the pond. Paul and his CEO need to come to the realization that their company is going to be burning cash until SurgiBot hits the market. That is the only product that matters to their business. Everything else is just a fluffer until it happens.

post

Submitting to FDA in May.

Surgical Robot Nearing FDA Submission | MDDI Medical Device and Diagnostic Industry News Products and Suppliers

Marie ThibaultTransEnterix expects to file its FDA 510(k) submission for the Senhance System by early May.After some slight delays over the past year, TransEnterix’s Senhance System is scheduled for an FDA 510(k) submission in the next couple months, with potential clearance expected this year.

post

Big news!

One step closer to FDA approval !

post

Loading...


Load More

Report this post

The reason we ask for your email address is to ensure the reporting feature is not abused. Once you report a post a confirmation email will be sent to you requiring that you did in fact mean to do this action. This also gives us a way to get in touch with you privately to discuss your reasoning if we feel the post has been reported without merit.

Your email address will never be used for any other reason and will never be sold to email marketers.

A reason is required.